Arrowhead shares rocketed 12% to close at 21.05 and ARWR stock leapfrogged its 50-day line, according to MarketSurge. Sarepta stock jumped too, 13.8% to 130.50, putting it above its 50-day moving ...

Arrowhead is also eligible for up to $10 billion in potential milestones and low double-digit royalties. Needham lowered Sarepta’s price target to $202 from $205, maintaining a ‘Buy’ rating.

Travis Kelce’s run onto the field for Friday’s game against the Raiders at Arrowhead Field hyped up the crowd — and the 360-degree camera that accompanied him showed all of it.

Sarepta Therapeutics is paying Arrowhead Pharmaceuticals $500 million in cash, plus a $325 million equity investment, for worldwide licensing rights to seven programs—four clinical and three ...